{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:49:13Z","timestamp":1788544153798,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T00:00:00Z","timestamp":1668643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T00:00:00Z","timestamp":1668643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Science and Development Programme of Suzhou","award":["SKY2021021"],"award-info":[{"award-number":["SKY2021021"]}]},{"name":"Science and Development Programme of Suzhou","award":["SKY2021021"],"award-info":[{"award-number":["SKY2021021"]}]},{"name":"Science and Development Programme of Suzhou","award":["SKY2021021"],"award-info":[{"award-number":["SKY2021021"]}]},{"name":"Science and Development Programme of Suzhou","award":["SKY2021021"],"award-info":[{"award-number":["SKY2021021"]}]},{"name":"Science and Development Programme of Suzhou","award":["SKY2021021"],"award-info":[{"award-number":["SKY2021021"]}]},{"name":"Science and Development Programme of Suzhou","award":["SKY2021021"],"award-info":[{"award-number":["SKY2021021"]}]},{"name":"Science and Development Programme of Suzhou","award":["SKY2021021"],"award-info":[{"award-number":["SKY2021021"]}]},{"name":"Science and Development Programme of Suzhou","award":["SKY2021021"],"award-info":[{"award-number":["SKY2021021"]}]},{"name":"Science and Development Programme of Suzhou","award":["SKY2021021"],"award-info":[{"award-number":["SKY2021021"]}]},{"name":"Science and Development Programme of Changshu","award":["CS2020016, CS202115"],"award-info":[{"award-number":["CS2020016, CS202115"]}]},{"name":"Science and Development Programme of Changshu","award":["CS2020016, CS202115"],"award-info":[{"award-number":["CS2020016, CS202115"]}]},{"name":"Science and Development Programme of Changshu","award":["CS2020016, CS202115"],"award-info":[{"award-number":["CS2020016, CS202115"]}]},{"name":"Science and Development Programme of Changshu","award":["CS2020016, CS202115"],"award-info":[{"award-number":["CS2020016, CS202115"]}]},{"name":"Science and Development Programme of Changshu","award":["CS2020016, CS202115"],"award-info":[{"award-number":["CS2020016, CS202115"]}]},{"name":"Science and Development Programme of Changshu","award":["CS2020016, CS202115"],"award-info":[{"award-number":["CS2020016, CS202115"]}]},{"name":"Science and Development Programme of Changshu","award":["CS2020016, CS202115"],"award-info":[{"award-number":["CS2020016, CS202115"]}]},{"name":"Science and Development Programme of Changshu","award":["CS2020016, CS202115"],"award-info":[{"award-number":["CS2020016, CS202115"]}]},{"name":"Science and Development Programme of Changshu","award":["CS2020016, CS202115"],"award-info":[{"award-number":["CS2020016, CS202115"]}]},{"name":"Youth Medical Talent Project of Suzhou","award":["GSWS2020106"],"award-info":[{"award-number":["GSWS2020106"]}]},{"name":"Youth Medical Talent Project of Suzhou","award":["GSWS2020106"],"award-info":[{"award-number":["GSWS2020106"]}]},{"name":"Youth Medical Talent Project of Suzhou","award":["GSWS2020106"],"award-info":[{"award-number":["GSWS2020106"]}]},{"name":"Youth Medical Talent Project of Suzhou","award":["GSWS2020106"],"award-info":[{"award-number":["GSWS2020106"]}]},{"name":"Youth Medical Talent Project of Suzhou","award":["GSWS2020106"],"award-info":[{"award-number":["GSWS2020106"]}]},{"name":"Youth Medical Talent Project of Suzhou","award":["GSWS2020106"],"award-info":[{"award-number":["GSWS2020106"]}]},{"name":"Youth Medical Talent Project of Suzhou","award":["GSWS2020106"],"award-info":[{"award-number":["GSWS2020106"]}]},{"name":"Youth Medical Talent Project of Suzhou","award":["GSWS2020106"],"award-info":[{"award-number":["GSWS2020106"]}]},{"name":"Youth Medical Talent Project of Suzhou","award":["GSWS2020106"],"award-info":[{"award-number":["GSWS2020106"]}]},{"name":"Programme of Key Clinical Diseases of Suzhou","award":["LCZX202125"],"award-info":[{"award-number":["LCZX202125"]}]},{"name":"Programme of Key Clinical Diseases of Suzhou","award":["LCZX202125"],"award-info":[{"award-number":["LCZX202125"]}]},{"name":"Programme of Key Clinical Diseases of Suzhou","award":["LCZX202125"],"award-info":[{"award-number":["LCZX202125"]}]},{"name":"Programme of Key Clinical Diseases of Suzhou","award":["LCZX202125"],"award-info":[{"award-number":["LCZX202125"]}]},{"name":"Programme of Key Clinical Diseases of Suzhou","award":["LCZX202125"],"award-info":[{"award-number":["LCZX202125"]}]},{"name":"Programme of Key Clinical Diseases of Suzhou","award":["LCZX202125"],"award-info":[{"award-number":["LCZX202125"]}]},{"name":"Programme of Key Clinical Diseases of Suzhou","award":["LCZX202125"],"award-info":[{"award-number":["LCZX202125"]}]},{"name":"Programme of Key Clinical Diseases of Suzhou","award":["LCZX202125"],"award-info":[{"award-number":["LCZX202125"]}]},{"name":"Programme of Key Clinical Diseases of Suzhou","award":["LCZX202125"],"award-info":[{"award-number":["LCZX202125"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Severe diseases like cirrhosis and liver failure can be developed from primary biliary cholangitis (PBC). Endothelin-2 (EDN2) and endothelin receptor B (EDNRB) are related to the pathogenesis of PBC. However, the roles of EDN2 and EDNRB in PBC-related liver injury and inflammation along with molecular mechanisms are poorly defined. In this study, histopathologic alterations of liver tissues were assessed through hematoxylin\u2013eosin staining. Alanine transaminase (ALT), alkaline phosphatase (ALP), aspartate transaminase (AST), and \u03b3-Glutamyltranspetidase (GGT) (4 liver function indexes) serum levels were detected with corresponding activity assay kits. Also, we determined the levels of M2 subtype anti-mitochondrial antibody (AMA-M2), interferon-gamma (IFN-\u03b3), and tumor-necrosis factor alpha (TNF\u03b1) in serum with ELISA assay. Later, RT-qPCR assay was used to measure the expression of genes at mRNA levels, while western blotting and immunohistochemical techniques were used to detect protein levels of genes. Our results showed that the liver tissues of PBC patients and mice presented with severe hepatocyte injury and inflammatory cell infiltration as well as destruction of intrahepatic small bile ducts. ALP, AST, ALT, GGT, AMA-M2, IFN-\u03b3, and TNF-\u03b1 serum levels were higher in PBC patients and mice. Besides, EDN2 and EDNRB were highly expressed in serums and livers of PBC patients and mice. EDNRB potentiated PBC-related liver injury and pro-inflammatory responses, as evidenced by observation of serious liver pathologic injury and increased serum levels of ALP, AST, ALT, AMA-M2, IFN-\u03b3, and TNF-\u03b1 in PBC mice following EDNRB overexpression. EDNRB overexpression or activation via its agonist IRL-1620 TFA triggered liver injury and pro-inflammatory responses, increased GRK2 expression and induced NF-\u03baB expression and activation in wild-type mice. EDNRB knockdown or inhibition by Bosentan alleviated liver damage and inflammation, reduced GRK2 expression, and inhibited NF-\u03baB in PBC mice. These findings suggested EDNRB loss or inhibition weakened liver injury and pro-inflammatory responses by down-regulating GRK2 and inhibiting the NF-\u03baB pathway in PBC mice.<\/jats:p>","DOI":"10.1038\/s41598-022-21816-x","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T12:03:43Z","timestamp":1668686623000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Endothelin receptor B enhances liver injury and pro-inflammatory responses by increasing G-protein-coupled receptor kinase-2 expression in primary biliary cholangitis"],"prefix":"10.1038","volume":"12","author":[{"given":"Guoxin","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenying","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaixing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyu","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuie","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingwang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,17]]},"reference":[{"key":"21816_CR1","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/hepr.12615","volume":"46","author":"S Shimoda","year":"2016","unstructured":"Shimoda, S. & Tanaka, A. It is time to change primary biliary cirrhosis (PBC): New nomenclature from \u201ccirrhosis\u201d to \u201ccholangitis\u201d, and upcoming treatment based on unveiling pathology. Hepatol. Res. 46, 407\u2013415. https:\/\/doi.org\/10.1111\/hepr.12615 (2016).","journal-title":"Hepatol. Res."},{"key":"21816_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3350\/cmh.2020.0028","volume":"27","author":"A Tanaka","year":"2021","unstructured":"Tanaka, A. Current understanding of primary biliary cholangitis. Clin. Mol. Hepatol. 27, 1\u201321. https:\/\/doi.org\/10.3350\/cmh.2020.0028 (2021).","journal-title":"Clin. Mol. Hepatol."},{"key":"21816_CR3","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41395-018-0390-3","volume":"114","author":"ZM Younossi","year":"2019","unstructured":"Younossi, Z. M. et al. Diagnosis and management of primary biliary cholangitis. Am. J. Gastroenterol. 114, 48\u201363. https:\/\/doi.org\/10.1038\/s41395-018-0390-3 (2019).","journal-title":"Am. J. Gastroenterol."},{"key":"21816_CR4","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1136\/gutjnl-2020-322362","volume":"70","author":"PJ Trivedi","year":"2021","unstructured":"Trivedi, P. J. & Hirschfield, G. M. Recent advances in clinical practice: Epidemiology of autoimmune liver diseases. Gut 70, 1989\u20132003. https:\/\/doi.org\/10.1136\/gutjnl-2020-322362 (2021).","journal-title":"Gut"},{"key":"21816_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bpg.2018.05.011","volume":"34\u201335","author":"R Rosa","year":"2018","unstructured":"Rosa, R., Cristoferi, L., Tanaka, A. & Invernizzi, P. Geoepidemiology and (epi-)genetics in primary biliary cholangitis. Best Pract. Res. Clin. Gastroenterol. 34\u201335, 11\u201315. https:\/\/doi.org\/10.1016\/j.bpg.2018.05.011 (2018).","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"21816_CR6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.bpg.2018.06.002","volume":"34\u201335","author":"A Janmohamed","year":"2018","unstructured":"Janmohamed, A. & Trivedi, P. J. Patterns of disease progression and incidence of complications in primary biliary cholangitis (PBC). Best Pract. Res. Clin. Gastroenterol. 34\u201335, 71\u201383. https:\/\/doi.org\/10.1016\/j.bpg.2018.06.002 (2018).","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"21816_CR7","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/s2468-1253(19)30343-7","volume":"5","author":"RA Shah","year":"2020","unstructured":"Shah, R. A. & Kowdley, K. V. Current and potential treatments for primary biliary cholangitis. Lancet Gastroenterol. Hepatol. 5, 306\u2013315. https:\/\/doi.org\/10.1016\/s2468-1253(19)30343-7 (2020).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"21816_CR8","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1161\/hypertensionaha.119.12105","volume":"74","author":"M Barton","year":"2019","unstructured":"Barton, M. & Yanagisawa, M. Endothelin: 30 years from discovery to therapy. Hypertension 74, 1232\u20131265. https:\/\/doi.org\/10.1161\/hypertensionaha.119.12105 (2019).","journal-title":"Hypertension"},{"key":"21816_CR9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.semnephrol.2015.02.002","volume":"35","author":"JJ Maguire","year":"2015","unstructured":"Maguire, J. J. & Davenport, A. P. Endothelin receptors and their antagonists. Semin. Nephrol. 35, 125\u2013136. https:\/\/doi.org\/10.1016\/j.semnephrol.2015.02.002 (2015).","journal-title":"Semin. Nephrol."},{"key":"21816_CR10","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/j.cellsig.2010.05.002","volume":"22","author":"AK Khimji","year":"2010","unstructured":"Khimji, A. K. & Rockey, D. C. Endothelin\u2013biology and disease. Cell Signal 22, 1615\u20131625. https:\/\/doi.org\/10.1016\/j.cellsig.2010.05.002 (2010).","journal-title":"Cell Signal"},{"key":"21816_CR11","doi-asserted-by":"publisher","first-page":"e1008947","DOI":"10.1371\/journal.ppat.1008947","volume":"16","author":"H Kong","year":"2020","unstructured":"Kong, H. et al. Endothelin receptors promote schistosomiasis-induced hepatic fibrosis via splenic B cells. PLoS Pathog. 16, e1008947. https:\/\/doi.org\/10.1371\/journal.ppat.1008947 (2020).","journal-title":"PLoS Pathog."},{"key":"21816_CR12","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1089\/hum.2018.166","volume":"30","author":"N Yadav","year":"2019","unstructured":"Yadav, N. et al. Efficient reconstitution of hepatic microvasculature by endothelin receptor antagonism in liver sinusoidal endothelial cells. Hum. Gene Ther. 30, 365\u2013377. https:\/\/doi.org\/10.1089\/hum.2018.166 (2019).","journal-title":"Hum. Gene Ther."},{"key":"21816_CR13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.yexmp.2019.02.002","volume":"107","author":"L Zhang","year":"2019","unstructured":"Zhang, L. et al. The clinical significance of endothelin receptor type B in hepatocellular carcinoma and its potential molecular mechanism. Exp. Mol. Pathol. 107, 141\u2013157. https:\/\/doi.org\/10.1016\/j.yexmp.2019.02.002 (2019).","journal-title":"Exp. Mol. Pathol."},{"key":"21816_CR14","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/liv.14757","volume":"41","author":"A Zipprich","year":"2021","unstructured":"Zipprich, A., Gittinger, F., Winkler, M., Dollinger, M. M. & Ripoll, C. Effect of ET-A blockade on portal pressure and hepatic arterial perfusion in patients with cirrhosis: A proof of concept study. Liver Int. 41, 554\u2013561. https:\/\/doi.org\/10.1111\/liv.14757 (2021).","journal-title":"Liver Int."},{"key":"21816_CR15","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1139\/cjpp-2019-0649","volume":"98","author":"GRT Ryanto","year":"2020","unstructured":"Ryanto, G. R. T., Yorifuji, K., Ikeda, K. & Emoto, N. Chondroitin sulfate mediates liver responses to injury induced by dual endothelin receptor inhibition. Can. J. Physiol. Pharmacol. 98, 618\u2013624. https:\/\/doi.org\/10.1139\/cjpp-2019-0649 (2020).","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"21816_CR16","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/j.1872-034X.2012.01021.x","volume":"42","author":"H Uehara","year":"2012","unstructured":"Uehara, H. et al. Endothelin-1 derived from spleen-activated Rho-kinase pathway in rats with secondary biliary cirrhosis. Hepatol. Res. 42, 1039\u20131047. https:\/\/doi.org\/10.1111\/j.1872-034X.2012.01021.x (2012).","journal-title":"Hepatol. Res."},{"key":"21816_CR17","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/s0168-8278(01)00045-9","volume":"34","author":"H Kojima","year":"2001","unstructured":"Kojima, H. et al. Endothelin-1 plays a major role in portal hypertension of biliary cirrhotic rats through endothelin receptor subtype B together with subtype A in vivo. J. Hepatol. 34, 805\u2013811. https:\/\/doi.org\/10.1016\/s0168-8278(01)00045-9 (2001).","journal-title":"J. Hepatol."},{"key":"21816_CR18","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/s0168-8278(00)80188-9","volume":"32","author":"H Kojima","year":"2000","unstructured":"Kojima, H. et al. Mixed endothelin receptor antagonist, SB209670, decreases portal pressure in biliary cirrhotic rats in vivo by reducing portal venous system resistance. J. Hepatol. 32, 43\u201350. https:\/\/doi.org\/10.1016\/s0168-8278(00)80188-9 (2000).","journal-title":"J. Hepatol."},{"key":"21816_CR19","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/j.1365-2036.2005.02307.x","volume":"21","author":"P Dimoulios","year":"2005","unstructured":"Dimoulios, P. et al. Ursodeoxycholic acid reduces increased circulating endothelin 2 in primary biliary cirrhosis. Aliment Pharmacol. Ther. 21, 227\u2013234. https:\/\/doi.org\/10.1111\/j.1365-2036.2005.02307.x (2005).","journal-title":"Aliment Pharmacol. Ther."},{"key":"21816_CR20","doi-asserted-by":"publisher","first-page":"111754","DOI":"10.1016\/j.biopha.2021.111754","volume":"140","author":"H Li","year":"2021","unstructured":"Li, H. et al. The pathogenesis, models and therapeutic advances of primary biliary cholangitis. Biomed. Pharmacother. 140, 111754. https:\/\/doi.org\/10.1016\/j.biopha.2021.111754 (2021).","journal-title":"Biomed. Pharmacother."},{"key":"21816_CR21","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1097\/MOG.0b013e32833755aa","volume":"26","author":"Y Ueno","year":"2010","unstructured":"Ueno, Y., Ambrosini, Y. M., Moritoki, Y., Ridgway, W. M. & Gershwin, M. E. Murine models of autoimmune cholangitis. Curr. Opin. Gastroenterol. 26, 274\u2013279. https:\/\/doi.org\/10.1097\/MOG.0b013e32833755aa (2010).","journal-title":"Curr. Opin. Gastroenterol."},{"key":"21816_CR22","doi-asserted-by":"publisher","first-page":"7579","DOI":"10.3748\/wjg.v22.i33.7579","volume":"22","author":"J Yang","year":"2016","unstructured":"Yang, J., Yu, Y. L., Jin, Y., Zhang, Y. & Zheng, C. Q. Clinical characteristics of drug-induced liver injury and primary biliary cirrhosis. World J. Gastroenterol. 22, 7579\u20137586. https:\/\/doi.org\/10.3748\/wjg.v22.i33.7579 (2016).","journal-title":"World J. Gastroenterol."},{"key":"21816_CR23","doi-asserted-by":"publisher","first-page":"49","DOI":"10.14218\/jcth.2019.00049","volume":"8","author":"A Galoosian","year":"2020","unstructured":"Galoosian, A., Hanlon, C., Zhang, J., Holt, E. W. & Yimam, K. K. Clinical updates in primary biliary cholangitis: Trends, epidemiology, diagnostics, and new therapeutic approaches. J. Clin. Transl. Hepatol. 8, 49\u201360. https:\/\/doi.org\/10.14218\/jcth.2019.00049 (2020).","journal-title":"J. Clin. Transl. Hepatol."},{"key":"21816_CR24","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1254\/jphs.13r02cr","volume":"123","author":"T Horinouchi","year":"2013","unstructured":"Horinouchi, T., Terada, K., Higashi, T. & Miwa, S. Endothelin receptor signaling: New insight into its regulatory mechanisms. J. Pharmacol. Sci. 123, 85\u2013101. https:\/\/doi.org\/10.1254\/jphs.13r02cr (2013).","journal-title":"J. Pharmacol. Sci."},{"key":"21816_CR25","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/cvr\/cvp392","volume":"85","author":"YJ Gao","year":"2010","unstructured":"Gao, Y. J. Desensitization of vascular endothelin receptors by G protein-coupled receptor kinase 2. Cardiovasc. Res. 85, 405\u2013406. https:\/\/doi.org\/10.1093\/cvr\/cvp392 (2010).","journal-title":"Cardiovasc. Res."},{"key":"21816_CR26","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1007\/s00018-019-03274-3","volume":"76","author":"P Penela","year":"2019","unstructured":"Penela, P., Ribas, C., S\u00e1nchez-Madrid, F. & Mayor, F. Jr. G protein-coupled receptor kinase 2 (GRK2) as a multifunctional signaling hub. Cell Mol. Life Sci. 76, 4423\u20134446. https:\/\/doi.org\/10.1007\/s00018-019-03274-3 (2019).","journal-title":"Cell Mol. Life Sci."},{"key":"21816_CR27","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3389\/fphar.2019.00112","volume":"10","author":"C Murga","year":"2019","unstructured":"Murga, C. et al. G protein-coupled receptor kinase 2 (GRK2) as a potential therapeutic target in cardiovascular and metabolic diseases. Front. Pharmacol. 10, 112. https:\/\/doi.org\/10.3389\/fphar.2019.00112 (2019).","journal-title":"Front. Pharmacol."},{"key":"21816_CR28","doi-asserted-by":"publisher","first-page":"35238","DOI":"10.1074\/jbc.273.52.35238","volume":"273","author":"P Penela","year":"1998","unstructured":"Penela, P., Ruiz-G\u00f3mez, A., Casta\u00f1o, J. G. & Mayor, F. Jr. Degradation of the G protein-coupled receptor kinase 2 by the proteasome pathway. J. Biol. Chem. 273, 35238\u201335244. https:\/\/doi.org\/10.1074\/jbc.273.52.35238 (1998).","journal-title":"J. Biol. Chem."},{"key":"21816_CR29","doi-asserted-by":"publisher","first-page":"110337","DOI":"10.1016\/j.cellsig.2022.110337","volume":"95","author":"H Cheng","year":"2022","unstructured":"Cheng, H. et al. G protein-coupled receptor kinase type 2 and \u03b2-arrestin2: Key players in immune cell functions and inflammation. Cell Signal 95, 110337. https:\/\/doi.org\/10.1016\/j.cellsig.2022.110337 (2022).","journal-title":"Cell Signal"},{"key":"21816_CR30","doi-asserted-by":"publisher","first-page":"822345","DOI":"10.3389\/fimmu.2021.822345","volume":"12","author":"N Li","year":"2021","unstructured":"Li, N. et al. G Protein-coupled receptor kinase 2 as novel therapeutic target in fibrotic diseases. Front. Immunol. 12, 822345. https:\/\/doi.org\/10.3389\/fimmu.2021.822345 (2021).","journal-title":"Front. Immunol."},{"key":"21816_CR31","doi-asserted-by":"publisher","first-page":"9277","DOI":"10.1021\/acs.jmedchem.5b01939","volume":"59","author":"M Guccione","year":"2016","unstructured":"Guccione, M. et al. G-protein-coupled receptor kinase 2 (GRK2) inhibitors: Current trends and future perspectives. J. Med. Chem. 59, 9277\u20139294. https:\/\/doi.org\/10.1021\/acs.jmedchem.5b01939 (2016).","journal-title":"J. Med. Chem."},{"key":"21816_CR32","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1161\/01.res.0000051884.27117.7e","volume":"92","author":"T Dschietzig","year":"2003","unstructured":"Dschietzig, T. et al. Relaxin, a pregnancy hormone, is a functional endothelin-1 antagonist: Attenuation of endothelin-1-mediated vasoconstriction by stimulation of endothelin type-B receptor expression via ERK-1\/2 and nuclear factor-kappaB. Circ. Res. 92, 32\u201340. https:\/\/doi.org\/10.1161\/01.res.0000051884.27117.7e (2003).","journal-title":"Circ. Res."},{"key":"21816_CR33","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.mvr.2011.12.001","volume":"83","author":"J Li","year":"2012","unstructured":"Li, J., Cao, Y. X., Liu, Y. & Xu, C. B. Minimally modified LDL upregulates endothelin type B receptors in rat basilar artery. Microvasc. Res. 83, 178\u2013184. https:\/\/doi.org\/10.1016\/j.mvr.2011.12.001 (2012).","journal-title":"Microvasc. Res."},{"key":"21816_CR34","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/bcpt.12123","volume":"113","author":"YH Xie","year":"2013","unstructured":"Xie, Y. H., Wang, S. W., Zhang, Y., Edvinsson, L. & Xu, C. B. Nuclear factor-kappaB-mediated endothelin receptor up-regulation increases renal artery contractility in rats. Basic Clin. Pharmacol. Toxicol. 113, 401\u2013410. https:\/\/doi.org\/10.1111\/bcpt.12123 (2013).","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"21816_CR35","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ejphar.2010.04.006","volume":"637","author":"JP Zheng","year":"2010","unstructured":"Zheng, J. P., Zhang, Y., Edvinsson, L., Hjalt, T. & Xu, C. B. NF-kappaB signaling mediates vascular smooth muscle endothelin type B receptor expression in resistance arteries. Eur. J. Pharmacol. 637, 148\u2013154. https:\/\/doi.org\/10.1016\/j.ejphar.2010.04.006 (2010).","journal-title":"Eur. J. Pharmacol."},{"key":"21816_CR36","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1002\/iub.2564","volume":"73","author":"Y Li","year":"2021","unstructured":"Li, Y. et al. CP-25 exerts therapeutic effects in mice with dextran sodium sulfate-induced colitis by inhibiting GRK2 translocation to downregulate the TLR4-NF-\u03baB-NLRP3 inflammasome signaling pathway in macrophages. IUBMB Life 73, 1406\u20131422. https:\/\/doi.org\/10.1002\/iub.2564 (2021).","journal-title":"IUBMB Life"},{"key":"21816_CR37","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1124\/mol.116.107698","volume":"92","author":"F Xu","year":"2017","unstructured":"Xu, F. et al. GRK2 mediates arginine vasopressin-induced interleukin-6 production via nuclear factor-\u03baB signaling neonatal rat cardiac fibroblast. Mol. Pharmacol. 92, 278\u2013284. https:\/\/doi.org\/10.1124\/mol.116.107698 (2017).","journal-title":"Mol. Pharmacol."},{"key":"21816_CR38","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jcmgh.2018.11.006","volume":"7","author":"Y Hitomi","year":"2019","unstructured":"Hitomi, Y. et al. NFKB1 and MANBA confer disease susceptibility to primary biliary cholangitis via independent putative primary functional variants. Cell Mol. Gastroenterol. Hepatol. 7, 515\u2013532. https:\/\/doi.org\/10.1016\/j.jcmgh.2018.11.006 (2019).","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"21816_CR39","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.26355\/eurrev_201905_17824","volume":"23","author":"Y Yu","year":"2019","unstructured":"Yu, Y. et al. A study of regulatory effects of TLR4 and NF-\u03baB on primary biliary cholangitis. Eur. Rev. Med. Pharmacol. Sci. 23, 3951\u20133959. https:\/\/doi.org\/10.26355\/eurrev_201905_17824 (2019).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"21816_CR40","doi-asserted-by":"publisher","first-page":"106386","DOI":"10.1016\/j.intimp.2020.106386","volume":"83","author":"Y Li","year":"2020","unstructured":"Li, Y. et al. Sirtuin 1 activation alleviates primary biliary cholangitis via the blocking of the NF-\u03baB signaling pathway. Int. Immunopharmacol. 83, 106386. https:\/\/doi.org\/10.1016\/j.intimp.2020.106386 (2020).","journal-title":"Int. Immunopharmacol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-21816-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-21816-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-21816-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T12:09:44Z","timestamp":1668686984000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-21816-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,17]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["21816"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-21816-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,17]]},"assertion":[{"value":"8 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19772"}}